Praxis Precision Medicines Inc (PRAX): Fair Value Consensus
Praxis Precision Medicines (PRAX) develops high-precision therapies for severe psychiatric and neurological disorders, leveraging the success of key drug candidates in late-stage trials. This chart shows the asset value is currently at 655.15. Meanwhile, supply chain disruptions and sanctions are hindering research efforts. The startup is currently focusing on its own R&D while seeking a major partner to bring its products to market.
Analytical breakdowns for Praxis Medicines (PRAX)
- share price and expert price forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Debt to Equity Ratio Praxis Precision Medicines|PRAX - Long-Term Debt to Capital|Current Liabilities to Capital Praxis Corp|PRAX - Company Total Debt|Debts to Book Capitalization Praxis Medicines|PRAX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Praxis Precision Medicines|Immediate Liquidity praxismedicines.com
- company profitability and valuation multiples indicators:
PRAX - Company Net Income|Forward Earnings Praxis Precision Medicines|PRAX - Price to Earnings Ratio|Future Price to Earnings Multiple Praxis Precision Medicines Inc|PRAX - PEG Multiple|EV/EBITDA Multiple Praxis Medicines|PRAX - Operating profit before deduction of amortization|Earnings per share for the last 12 months Praxis Precision Medicines|PRAX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months praxismedicines.com|PRAX - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Praxis Precision Medicines
Summary company analytics:PRAX praxismedicines.com
Praxis Precision Medicines (PRAX) is burning through its existing capital on costly clinical trials for anti-epileptic drugs in the absence of revenue. The consensus forecast integrates DCF models and industry risks from leading investment banks into a single average target. Investors should view this indicator as an integral barometer of the asset's fair value. The historical trend of analyst targets reflects a reassessment of the company's prospects. This benchmark helps avoid impulsive trades.
Competitors of Praxis Precision Medicines
BIIB: Forecast Levels Chart|Price Target Chart Neurocrine Biosciences, Inc. NBIX|Fair Value Consensus RGC|Axsome Therapeutics Inc - Analyst Consensus Forecast|ACAD - Analyst Consensus Forecast|XENE (Xenon Pharmaceuticals) - Consensus Target|Broker Consensus Forecast VKTX|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus AVXL (Anavex)|CeriBell Corp (CBLL) - Price Target Chart|Average Forecast Price Prothena Corporation plc (PRTA)|Price Target Chart Alector Inc.|annexonbio.com - Forecast Levels Chart|Price Target Chart Omeros Corporation (OMER)|NGNE (Neurogene Inc) - Fair Value Consensus|Analyst Consensus Forecast ACIU (AC Immune Corp)|Analyst Consensus Forecast Voyager Corp VYGR|NMRA: Consensus Target|SCLX (scilexholding.com) - Broker Consensus Forecast|TVGN: Analyst Consensus Forecast|ACOG - Analyst Median Target|Price Target Chart Cognition Therapeutics|Inhibikase Pharma (IKT) - Analyst Median Target|Consensus Target SAVA (Cassava Sciences, Inc.)|ASRT (assertiotx.com) - Fair Value Consensus|Price Target Chart Coya Therapeutics COYA|VTGN (VistaGen Therapeutics, Inc.) - Forecast Levels Chart|OVID - Price Target Chart|Fair Value Consensus ABOS (Acumen Pharmaceuticals, Inc)|CRVO: Analyst Consensus Forecast|Average Forecast Price Alterity Therapeutics Limited (ATHE)|CLNN (Clene Inc) - Analyst Consensus Forecast|Consensus Target PepGen Corp (PEPG)|Analyst Consensus Forecast JUNS|Analyst Median Target Relmada Corp|Price Target Chart Annovis Bio, Inc. ANVS|Analyst Median Target Grace Therapeutics Inc (GRCE)|Firefly Neuroscience - Analyst Consensus Forecast|Analyst Median Target Klotho Neurosciences Inc KLTO|neurosense-tx.com (NRSN) - Price Target Chart|Average Forecast Price Reviva Pharmaceuticals, Inc. (RVPH)|Price Target Chart MetaVia Inc.|Broker Consensus Forecast NRXS (neuraxis.com)|Consensus Target HSDT (Helius Medical)|PASG (passagebio.com) - Fair Value Consensus|Price Target Chart Neuphoria Therapeutics NEUP|NERV - Consensus Target|Athira Pharma, Inc. - Analyst Consensus Forecast|Average Forecast Price addextherapeutics.com|ALZN: Analyst Consensus Forecast|Broker Consensus Forecast CYCN|PTIX (Protagenic Therapeutics Inc.) - Analyst Consensus Forecast|Pasithea (KTTA) - Analyst Median Target|Analyst Consensus Forecast CRGT|Consensus Target avenuetx.com ATXI|Analyst Consensus Forecast BCLI (BrainStorm Cell Therapeutics)|Analyst Median Target Cara Therapeutics Inc. (CARA)|CHRO - Price Target Chart|ELYM (Eliem Therapeutics) - Broker Consensus Forecast|ITCI: Analyst Consensus Forecast|Average Forecast Price longboardpharma.com (LBPH)|Price Target Chart Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc (NKGN) - Analyst Median Target|Price Target Chart NeuroBo (NRBO)|SAGE: Forecast Levels Chart|Price Target Chart Synaptogenix, Inc. SNPX|Fair Value Consensus TRVN|Vigil Neuro - Analyst Consensus Forecast|WENA - Analyst Consensus Forecast|CERE (Cerevel) - Consensus Target
